))
Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser
Manage episode 380166964 series 3369804
Sisällön tarjoaa Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.
Here are the shownotes:
1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:
https://x.com/Rfonsi1/status/1206004966294294528?s=20
2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:
https://pubmed.ncbi.nlm.nih.gov/28655925/
3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):
https://pubmed.ncbi.nlm.nih.gov/33129376/
4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:
https://pubmed.ncbi.nlm.nih.gov/36779691/
5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):
https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0
6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34388020/
7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:
45 jaksoa
Jaa
